Streetbeat News

CNSP

CNS Pharmaceuticals, Inc.

https://www.cnspharma.com

Industry

Biotechnology

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Open

0.13

Mkt cap

7.5M

Volume

33M

High

0.14

P/E Ratio

N/A

52-wk high

121.00

Low

0.13

Div yield

N/A

52-wk low

0.10

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Thursday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

Tesla shares surged by 10.8% in pre-market trading after reporting better-than-expected Q3 earnings. Several other stocks also showed significant pre-market movements, including CCSC Technology, Mobile-health Network Solutions, and CNS Pharmaceuticals among gainers, while SaverOne 2014 and Gold Resource Corporation were among the losers.

Portfolio Pulse from Avi Kapoor

October 24, 2024 | 10:21 am

Several healthcare stocks experienced significant price movements in Wednesday's after-market session. CNS Pharma, DBV Technologies, and Molina Healthcare were among the gainers, while Enveric Biosciences and Evotec saw declines. Molina Healthcare's rise is linked to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 8:31 pm

U.S. stocks fell with the NASDAQ down 2% and the S&P 500 down over 1%. Crude oil inventories rose significantly more than expected. La Rosa Holdings, CNS Pharmaceuticals, and Virax Biolabs saw significant stock price increases, while Alto Neuroscience, Constellium, and Enphase Energy experienced declines due to various company-specific news.

Portfolio Pulse from Avi Kapoor

October 23, 2024 | 6:30 pm

U.S. stocks fell with the Nasdaq down over 1%. AT&T reported better-than-expected earnings, boosting its stock. La Rosa Holdings, CNS Pharmaceuticals, and Virax Biolabs saw significant stock gains, while Alto Neuroscience, Constellium, and Enphase Energy faced declines due to disappointing results.

Portfolio Pulse from Avi Kapoor

October 23, 2024 | 4:44 pm

Several health care stocks experienced significant price movements during Wednesday's intraday session. CNS Pharma, Virax Biolabs Group, and Tevogen Bio Holdings were among the top gainers, while Alto Neuroscience and Silexion Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:31 pm

CNS Pharmaceuticals (CNSP) stock surged 86% after receiving a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company is ineligible for a 180-day extension due to past reverse stock splits and has requested a hearing on November 5 to delay delisting.

Portfolio Pulse from Henry Khederian

October 23, 2024 | 2:08 pm

U.S. stocks fell with the Dow dropping over 250 points. Boeing reported a Q3 loss, missing revenue and EPS expectations. Utilities rose, while consumer discretionary fell. La Rosa Holdings, CNS Pharmaceuticals, and Virax Biolabs saw significant stock gains, while Alto Neuroscience, Ensysce Biosciences, and Aptevo Therapeutics experienced declines.

Portfolio Pulse from Avi Kapoor

October 23, 2024 | 1:50 pm

CNS Pharmaceuticals shares are trading higher following the company's request for a panel hearing on November 5, 2024. The decision on suspension or delisting will be on hold until the hearing.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.